Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | PDE4A | P27815 | 4/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053827 | 1.00 | ALDH1A1 (0.62) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL6203345 | 0.90 | ALDH1A1 (0.74) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL29160363 | 0.86 | ALDH1A1 (0.79) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL29160472 | 0.82 | ALDH1A1 (0.90) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL29160275 | 0.78 | ALDH1A1 (0.67) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL6673822 | 0.77 | ALDH1A1 (0.51) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL6677049 | 0.77 | TSHR (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL22014331 | 0.77 | TSHR (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL22014067 | 0.77 | TSHR (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 | |
| SCHEMBL6673825 | 0.75 | TSHR (0.55) | ALDH1A1RAB9ANPC1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| CN-101326275-A | Multifunctional ionic liquid composition | UNIV ALABAMA (US) | 2008-12-17 | — | — | CN | claimed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| US-6986901-B2 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-17 | — | — | US | claimed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | claimed |
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | MCNEIL-PPC, INC | 2005-06-23 | — | — | US | claimed |
| EP-1531801-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004006902-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20040013741-A1 | Gastrointestinal compositions | JOHNSON & JOHNSON CONSUMER INC. | 2004-01-22 | — | — | US | claimed |
| WO-2004006901-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20040010035-A1 | Gastrointestinal compositions | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | claimed |
| US-20040010034-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| US-20040009234-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-116234549-A | Salt-induced kinase inhibitors | 总医院公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20230105412-A1 | 5-HT3 RECEPTOR MODULATOR, THE CRYSTALLINE FORM, METHODS OF MAKING, AND USE THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2023-04-06 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| WO-2021188563-A1 | 5-HT3 RECEPTOR MODULATOR, THE CRYSTALLINE FORM, METHODS OF MAKING, AND USE THEREOF | CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188564-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021076922-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| US-10980756-B1 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-08-27 | — | — | US | disclosed |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10583086-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10231938-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3344274-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Bio, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20180071219-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180028449-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2018-02-01 | — | — | US | disclosed |
| CN-103271083-B | Multi-functional ionic liquid compositions | 阿拉巴马大学 | 2017-08-11 | — | — | CN | disclosed |
| US-9682043-B2 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170079920-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2017-03-23 | — | — | US | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160235675-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-1807033-B1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMA (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160128949-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150359746-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-12-17 | — | — | US | disclosed |
| US-20150290134-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9155712-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| CN-104758253-A | Technology for preparation of macromolecular microspheres | NEXBIO INC | 2015-07-08 | — | — | CN | disclosed |
| US-20150157578-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9045501-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150050713-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8815281-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140234443-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-8784893-B2 | Polymer formulations for delivery of bioactive agents | CARBYLAN THERAPEUTICS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| CN-102573913-B | Biodegradable polyethylene glycol-based water-insoluble hydrogels | ASCENDIS PHARMA AS | 2014-06-18 | — | — | CN | disclosed |
| US-20140134150-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-103784408-A | Technology for the preparation of microparticles | ANSUN BIOPHARMA INC | 2014-05-14 | — | — | CN | disclosed |
| US-8710046-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710047-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140099696-A1 | Technology for the Preparation of Microparticles | ANSUN BIOPHARMA, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8623419-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8591941-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | disclosed |
| CN-103271083-A | Multi-functional ionic liquid compositions | UNIV ALABAMA | 2013-09-04 | — | — | CN | disclosed |
| CN-102046176-B | 5-HT3Receptor modulators, methods of preparation and uses thereof | ALBANY MOLECULAR RES INC | 2013-08-07 | — | — | CN | disclosed |
| US-8501729-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| CN-101326275-B | Multifunctional ionic liquid composition | UNIV ALABAMA | 2013-06-05 | — | — | CN | disclosed |
| US-8414914-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| US-20120308644-A1 | Compositions for mucosal delivery of agents | ARCHIMEDES LABORATORIES, INC. | 2012-12-06 | — | — | US | disclosed |
| US-20120270857-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120269881-A9 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8252323-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1768647-B1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | VIRUN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120165762-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| CN-102510862-A | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RES INC | 2012-06-20 | — | — | CN | disclosed |
| US-20120141590-A1 | Technology for the Preparation of Microparticles | MALAKHOV MICHAEL (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2459563-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120116062-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. | 2012-05-10 | — | — | US | disclosed |
| US-8124600-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| CN-101005828-B | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents | VIRUN INC | 2012-01-11 | — | — | CN | disclosed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110117184-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2011-05-19 | — | — | US | disclosed |
| CN-102046176-A | 5-HT3Receptor modulators, methods of preparation and uses thereof | ALBANY MOLECULAR RES INC | 2011-05-04 | — | — | CN | disclosed |
| US-20110097384-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| EP-2310019-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7906140-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN THERAPEUTICS, INC. | 2011-02-10 | — | — | US | disclosed |
| WO-2011008572-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| CN-101848704-A | Techniques for preparing microparticles | NEXBIO INC | 2010-09-29 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166874-A1 | Technology for Preparation of Macromolecular Microspheres | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-01 | — | — | US | disclosed |
| EP-2173327-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | Nexbio, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009155054-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2117513-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | Carbylan Biosurgery, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090098207-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| CN-101404980-A | Preparation Technology of Macromolecular Microspheres | NEXBIO INC (US) | 2009-04-08 | — | — | CN | disclosed |
| WO-2009015286-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | NEXBIO, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1740201-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INTERFERON-TAU | PEPGEN CORP (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1981483-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | Nexbio, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008098019-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN BIOSURGERY, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080025948-A1 | Methods of Treatment Using Interferon-Tau | PEPGEN CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080008741-A1 | Methods of Treating Irritable Bowel Syndrome | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| WO-2007114881-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070190163-A1 | Technology for preparation of macromolecular microspheres | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH | 2007-08-16 | — | — | US | disclosed |
| CN-101005828-A | Compositions comprising a mucoadhesive protein and an activeprinciple for mucosal delivery of said agents | VIRUN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1807033-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| EP-1768647-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | Virun, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1740201-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INTERFERON-TAU | Pepgen Corporation (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1727520-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1718148-A2 | METHODS OF TREATING IRRITABLE BOWEL SYNDROME | The Regents of the University of California (US) | 2006-11-08 | — | — | EP | disclosed |
| US-7125848-B2 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7122198-B1 | Fast dissolving composition with prolonged sweet taste | PANACEA BIOTEC LIMITED (IN) | 2006-10-17 | — | — | US | disclosed |
| WO-2006044206-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060078604-A1 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-7026360-B1 | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients | INPHARMA S.A. (CH) | 2006-04-11 | — | — | US | disclosed |
| WO-2006009825-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENTS | VIRUN, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-6986901-B2 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-17 | — | — | US | disclosed |
| WO-2006001815-A1 | ACTIVE AGENTS USING LIPOSOME MACRO-BEADS | SUVANPRAKORN PICHIT (TH) | 2006-01-05 | — | — | WO | disclosed |
| EP-1021204-B1 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMA (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050281772-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2005-12-22 | — | — | US | disclosed |
| US-20050226845-A1 | Method of treatment using interferon-tau | PEPGEN CORPORATION | 2005-10-13 | — | — | US | disclosed |
| WO-2005087254-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INTERFERON-TAU | PEPGEN CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005076824-A2 | METHODS OF TREATING IRRITABLE BOWEL SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050181041-A1 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | MCNEIL-PPC, INC | 2005-06-23 | — | — | US | disclosed |
| WO-2005055983-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1531801-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050026835-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005000285-A2 | METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| CN-1178699-C | Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients | — | 2004-12-08 | — | — | CN | disclosed |
| US-20040224012-A1 | Topical application and methods for administration of active agents using liposome macro-beads | BIOPHILE CORPORATION LTD. (TH) | 2004-11-11 | — | — | US | disclosed |
| US-20040018241-A1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2004006902-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20040013741-A1 | Gastrointestinal compositions | JOHNSON & JOHNSON CONSUMER INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2004006901-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20040010035-A1 | Gastrointestinal compositions | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | disclosed |
| US-20040010034-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | disclosed |
| US-20040009234-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | disclosed |
| US-6638528-B1 | Pressure-sensitive adhesive matrix comprising blend of polyacrylate, polysiloxane, polyisobutylene, polyisoprene, polyamide or polystyrene; and insoluble, non-adhesive ethyl cellulose; polyvinylpyrrolidone crystallization inhibitor | NOVEN PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| US-6562363-B1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| WO-2003030818-A2 | ACTIVE AGENTS USING LIPOSOME BEADS | SUVANPRAKORN PICHIT (TH) | 2003-04-17 | — | — | WO | disclosed |
| US-20030068365-A1 | Compositions and methods for administration of active agents using liposome beads | BIOPHILE CORPORATION, LTD. (TH) | 2003-04-10 | — | — | US | disclosed |
| EP-1235561-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | Panacea Biotec Limited (IN) | 2002-09-04 | — | — | EP | disclosed |
| US-20020004065-A1 | Compositions and methods to effect the release profile in the transdermal administration of active agents | KANIOS DAVID (US) | 2002-01-10 | — | — | US | disclosed |
| WO-2001039749-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | PANACEA BIOTEC LIMITED (IN) | 2001-06-07 | — | — | WO | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
| US-6221383-B1 | BLEND OF AT LEAST TWO POLYMERS, OR AT LEAST ONE POLYMER AND A SOLUBLE POLYVINYLPYRROLIDONE, IN COMBINATION WITH A DRUG PROVIDES A PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR A TRANSDERMAL DRUG DELIVERY SYSTEM | NOVEN PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1021204-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-4470690-A | Removably mounted electrophotographic belt assembly for electrophotographic copier | TETRAS, S.A. (FR) | 1984-09-11 | — | — | US | disclosed |
| US-4470690-A | Removably mounted electrophotographic belt assembly for electrophotographic copier | TETRAS, S.A. (FR) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | ALDH1A1 2937/4885RAB9A 1335/4885NPC1 295/4885 |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | ALDH1A1 2230/4885RAB9A 2223/4885NPC1 2396/4885 |
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | ALDH1A1 2992/4885RAB9A 1286/4885NPC1 4707/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | ALDH1A1 2937/4885RAB9A 1335/4885NPC1 295/4885 |
| US-20120270857-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | ALDH1A1 2992/4885RAB9A 1286/4885NPC1 4707/4885 |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2174/4885RAB9A 2185/4885NPC1 2192/4885 |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2174/4885RAB9A 2185/4885NPC1 2192/4885 |
| US-20040010034-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ALDH1A1 1487/4885RAB9A 582/4885NPC1 1849/4885 |
| US-20040013741-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ALDH1A1 1487/4885RAB9A 582/4885NPC1 1849/4885 |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | ALDH1A1 3381/4885RAB9A 3517/4885NPC1 2362/4885 |
| US-20140234443-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | ALDH1A1 2992/4885RAB9A 1286/4885NPC1 4707/4885 |
| US-20040009234-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ALDH1A1 1487/4885RAB9A 582/4885NPC1 1849/4885 |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | CACNB2, RYR2, FABP2 | ALDH1A1 4216/4885RAB9A 2212/4885NPC1 1233/4885 |
| US-20040010035-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ALDH1A1 1487/4885RAB9A 582/4885NPC1 1849/4885 |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | NCSTN, CACNA1B, CACNA1A | ALDH1A1 3307/4885RAB9A 741/4885NPC1 898/4885 |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | ALDH1A1 2174/4885RAB9A 2185/4885NPC1 2192/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ALDH1A1 2230/4885RAB9A 2223/4885NPC1 2396/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | ALDH1A1 3497/4885RAB9A 424/4885NPC1 1467/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2174/4885RAB9A 2185/4885NPC1 2192/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ALDH1A1 1053/4885RAB9A 4071/4885NPC1 4802/4885 |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | ALDH1A1 2992/4885RAB9A 1286/4885NPC1 4707/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ALDH1A1 3977/4885RAB9A 610/4885NPC1 1662/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | ALDH1A1 3977/4885RAB9A 610/4885NPC1 1662/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ALDH1A1 2238/4885RAB9A 2227/4885NPC1 2385/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ALDH1A1 3889/4885RAB9A 648/4885NPC1 1995/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ALDH1A1 72/4885RAB9A 146/4885NPC1 528/4885 |
| US-20050026835-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | CACNB2, RYR2, FABP2 | ALDH1A1 4216/4885RAB9A 2212/4885NPC1 1233/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | ALDH1A1 204/4885RAB9A 3125/4885NPC1 1629/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | ALDH1A1 3889/4885RAB9A 648/4885NPC1 1995/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ALDH1A1 3889/4885RAB9A 648/4885NPC1 1995/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | ALDH1A1 3146/4885RAB9A 1723/4885NPC1 531/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | ALDH1A1 2305/4885RAB9A 2086/4885NPC1 2227/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ALDH1A1 1053/4885RAB9A 4071/4885NPC1 4802/4885 |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | ALDH1A1 2992/4885RAB9A 1286/4885NPC1 4707/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ALDH1A1 72/4885RAB9A 146/4885NPC1 528/4885 |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | BMP2, BMP6, BMP4 | ALDH1A1 3390/4885RAB9A 2213/4885NPC1 3106/4885 |
| US-10980756-B1 | Methods of treatment | ACE2, ACE, SI | ALDH1A1 3977/4885RAB9A 610/4885NPC1 1662/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | ALDH1A1 2641/4885RAB9A 687/4885NPC1 792/4885 |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2168/4885RAB9A 2177/4885NPC1 2220/4885 |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ALDH1A1 2230/4885RAB9A 2223/4885NPC1 2396/4885 |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ALDH1A1 2230/4885RAB9A 2223/4885NPC1 2396/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ALDH1A1 2230/4885RAB9A 2223/4885NPC1 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.